Management of Hepatitis B Virus Infection in Liver Transplant Recipients
Hepatitis B virus (HBV)-related liver disease is a common indication for liver transplantation (LT) in Asian countries.1 When left untreated, the overall five-year survival rate in HBV-related cirrhosis is 71%, which in cases of decompensated cirrhosis decreases to 14%.2 In the 1980s, hepatitis B-re...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2013-12-01
|
| Series: | European Medical Journal Hepatology |
| Subjects: | |
| Online Access: | http://emjreviews.com/wp-content/uploads/8.-JoyVarghese-et-al..pdf |
| _version_ | 1818905997525123072 |
|---|---|
| author | Joy Varghese Jayanthi Venkataraman Mettu Srinivas Reddy Mohamed Rela |
| author_facet | Joy Varghese Jayanthi Venkataraman Mettu Srinivas Reddy Mohamed Rela |
| author_sort | Joy Varghese |
| collection | DOAJ |
| description | Hepatitis B virus (HBV)-related liver disease is a common indication for liver transplantation (LT) in Asian countries.1 When left untreated, the overall five-year survival rate in HBV-related cirrhosis is 71%, which in cases of decompensated cirrhosis decreases to 14%.2 In the 1980s, hepatitis B-related acute liver failure and chronic liver disease (CLD) were considered contraindications for LT because of almost universal graft reinfection and high rates of graft and recipient failure (>50%).3-4 These patients had severe and rapidly progressive liver disease with a two-year graft and patient survival of 50% compared to 80% in those transplanted for non-HBV-related CLD.5 As a result, there were fewer LT for HBV liver disease for several years.6 However, with the introduction of nucleoside and nucleotide analogues and the use of intra and post- operative hepatitis B immunoglobulin (HBIG), there was renewed interest in the application of LT in these patients. There was a significant decrease in post-operative HBV recurrence rates.7-9 The current overall survival of patients transplanted for HBV-related cirrhosis has improved to 85% at one year, and 75% at five years.7,10-12 The present review highlights issues pertaining to HBV reinfection and de novo infection in LT recipients with recommendations for its management. |
| first_indexed | 2024-12-19T21:32:13Z |
| format | Article |
| id | doaj.art-778457c350f243b18b875ff5fb4253fb |
| institution | Directory Open Access Journal |
| issn | 2053-4221 |
| language | English |
| last_indexed | 2024-12-19T21:32:13Z |
| publishDate | 2013-12-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal Hepatology |
| spelling | doaj.art-778457c350f243b18b875ff5fb4253fb2022-12-21T20:04:53ZengEuropean Medical JournalEuropean Medical Journal Hepatology2053-42212013-12-01115867Management of Hepatitis B Virus Infection in Liver Transplant RecipientsJoy Varghese0Jayanthi Venkataraman1Mettu Srinivas Reddy2Mohamed Rela3Institute of Liver Diseases & Transplantation, Global Hospitals & Health City, Chennai, IndiaInstitute of Liver Diseases & Transplantation, Global Hospitals & Health City, Chennai, IndiaInstitute of Liver Diseases & Transplantation, Global Hospitals & Health City, Chennai, IndiaInstitute of Liver Diseases & Transplantation, Global Hospitals & Health City, Chennai, India, Kings College Hospital, London, United KingdomHepatitis B virus (HBV)-related liver disease is a common indication for liver transplantation (LT) in Asian countries.1 When left untreated, the overall five-year survival rate in HBV-related cirrhosis is 71%, which in cases of decompensated cirrhosis decreases to 14%.2 In the 1980s, hepatitis B-related acute liver failure and chronic liver disease (CLD) were considered contraindications for LT because of almost universal graft reinfection and high rates of graft and recipient failure (>50%).3-4 These patients had severe and rapidly progressive liver disease with a two-year graft and patient survival of 50% compared to 80% in those transplanted for non-HBV-related CLD.5 As a result, there were fewer LT for HBV liver disease for several years.6 However, with the introduction of nucleoside and nucleotide analogues and the use of intra and post- operative hepatitis B immunoglobulin (HBIG), there was renewed interest in the application of LT in these patients. There was a significant decrease in post-operative HBV recurrence rates.7-9 The current overall survival of patients transplanted for HBV-related cirrhosis has improved to 85% at one year, and 75% at five years.7,10-12 The present review highlights issues pertaining to HBV reinfection and de novo infection in LT recipients with recommendations for its management.http://emjreviews.com/wp-content/uploads/8.-JoyVarghese-et-al..pdfCirrhosisHepatitis B Virus (HBV)Liver TransplantionNucleosideNucleotide |
| spellingShingle | Joy Varghese Jayanthi Venkataraman Mettu Srinivas Reddy Mohamed Rela Management of Hepatitis B Virus Infection in Liver Transplant Recipients European Medical Journal Hepatology Cirrhosis Hepatitis B Virus (HBV) Liver Transplantion Nucleoside Nucleotide |
| title | Management of Hepatitis B Virus Infection in Liver Transplant Recipients |
| title_full | Management of Hepatitis B Virus Infection in Liver Transplant Recipients |
| title_fullStr | Management of Hepatitis B Virus Infection in Liver Transplant Recipients |
| title_full_unstemmed | Management of Hepatitis B Virus Infection in Liver Transplant Recipients |
| title_short | Management of Hepatitis B Virus Infection in Liver Transplant Recipients |
| title_sort | management of hepatitis b virus infection in liver transplant recipients |
| topic | Cirrhosis Hepatitis B Virus (HBV) Liver Transplantion Nucleoside Nucleotide |
| url | http://emjreviews.com/wp-content/uploads/8.-JoyVarghese-et-al..pdf |
| work_keys_str_mv | AT joyvarghese managementofhepatitisbvirusinfectioninlivertransplantrecipients AT jayanthivenkataraman managementofhepatitisbvirusinfectioninlivertransplantrecipients AT mettusrinivasreddy managementofhepatitisbvirusinfectioninlivertransplantrecipients AT mohamedrela managementofhepatitisbvirusinfectioninlivertransplantrecipients |